You are here: Industry Insights > RRMM

News List

Antengene Submits New Drug Application for Selinexor in Taiwan, China for the Treatment of Three Indications in Hematologic Malignancies prnasia
July 14, 2021
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has ...
Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021 prnasia
June 04, 2021
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, announced that the results from ...
Janssen’s myeloma CAR T therapy cilta-cel demonstrates ‘sustained efficacy’ pharmatimes
June 03, 2021
Janssen has reported new data for its B-cell maturation antigen (BCMA) directed CAR T therapy ciltacabtagene autoleucel (cilta-cel) in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients.
Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment prnasia
April 29, 2021
With the official release and implementation of the Overall Plan for the Construction of Hainan Free Trade Port, patient can now access global innovative medicines in mainland China.
FDA green light for Sarclisa combo in multiple myeloma pharmatimes
April 01, 2021
French pharma company Sanofi has received US Food and Drug Administration (FDA) approval for its CD38 inhibitor Sarclisa in combination with carfilzomib and dexamethasone (Kd) for the treatment of advanced multiple myeloma.
Antengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China's NMPA prnasia
February 24, 2021
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, today announced that China's ...
Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM prnasia
January 28, 2021
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced that the ...
Antengene Announces Approval of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM prnasia
December 18, 2020
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced that the ...
CARsgen Therapeutics Presents Updated Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition prnasia
December 07, 2020
CARsgen Therapeutics announced updated safety and efficacy results from its ongoing global clinical studies of CT053, an investigational chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed and/or refractory multiple myeloma (RRMM).
Patient Preferences Explored in Multiple Myeloma Treatment drugs
August 21, 2019
An Eastern Cooperative Oncology Group (ECOG) performance status of ≥2 is linked to lower treatment satisfaction in patients with relapsed or refractory multiple myeloma (RRMM)...